Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024

Rhea-AI Summary

Dynavax Technologies Corporation (DVAX) will report its Q4 and full year 2023 financial results on February 22, 2024, after the U.S. financial markets close. The company will also host a conference call and live audio webcast on the same day. The live audio webcast can be accessed through the 'Events & Presentations' page on the 'Investors' section of the Company's website. A replay of the webcast will be available for 30 days. Participants can register for the call using the caller registration link and are recommended to dial in or log into the webcast 10 minutes prior to the call.

EMERYVILLE, Calif., Feb. 8, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, February 22, 2024, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For Investors/Media:

Paul Cox
pcox@dynavax.com
510-665-0499 

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-conference-call-on-february-22-2024-302058032.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax Technologies Corporation report its Q4 and full year 2023 financial results?

Dynavax Technologies Corporation (DVAX) will report its Q4 and full year 2023 financial results on February 22, 2024, after the U.S. financial markets close.

How can the live audio webcast be accessed?

The live audio webcast can be accessed through the 'Events & Presentations' page on the 'Investors' section of the Company's website at https://investors.dynavax.com/events-presentations.

For how long will the replay of the webcast be available?

A replay of the webcast will be available for 30 days following the live event.

What is the recommended time for participants to dial into the conference call or log into the webcast?

It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.